HomeCompareGMALY vs JNJ

GMALY vs JNJ: Dividend Comparison 2026

GMALY yields 3.06% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.1K in total portfolio value· pulled ahead in Year 5
10 years
GMALY
GMALY
● Live price
3.06%
Share price
$14.05
Annual div
$0.43
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.31
Full GMALY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — GMALY vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGMALYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GMALY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GMALY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GMALY
Annual income on $10K today (after 15% tax)
$260.10/yr
After 10yr DRIP, annual income (after tax)
$0.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GMALY + JNJ for your $10,000?

GMALY: 50%JNJ: 50%
100% JNJ50/50100% GMALY
Portfolio after 10yr
$25.2K
Annual income
$2,344.85/yr
Blended yield
9.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GMALY
No analyst data
Altman Z
1.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GMALY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGMALYJNJ
Forward yield3.06%2.13%
Annual dividend / share$0.43$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.2K$30.3K
Annual income after 10y$0.31$4,689.40
Total dividends collected$309.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GMALY vs JNJ ($10,000, DRIP)

YearGMALY PortfolioGMALY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,853$153.00$10,592$272.30+$261.00GMALY
2$11,690$77.59$11,289$357.73+$401.00GMALY
3$12,548$39.06$12,123$472.89+$425.00GMALY
4$13,446$19.59$13,141$629.86+$305.00GMALY
5← crossover$14,397$9.81$14,408$846.81$11.00JNJ
6$15,409$4.91$16,021$1,151.60$612.00JNJ
7$16,490$2.45$18,122$1,588.22$1.6KJNJ
8$17,646$1.23$20,930$2,228.20$3.3KJNJ
9$18,882$0.61$24,792$3,191.91$5.9KJNJ
10$20,204$0.31$30,274$4,689.40$10.1KJNJ

GMALY vs JNJ: Complete Analysis 2026

GMALYStock

Genting Malaysia Berhad, together with its subsidiaries, engages in the leisure and hospitality business in Malaysia, the United Kingdom, Egypt, the United States, and the Bahamas. It operates through Leisure & Hospitality, and Properties segments. The Leisure & Hospitality segment comprises integrated resort activities, which include gaming, hotels, food and beverage, theme parks, and retail and entertainment attractions, as well as tours and travel related, and other supporting services. The Properties segment is involved in the development and sale of land and properties, as well as letting of apartment units; and property investment and management activities. It also engages in the operation of casinos; and provision of information technology and consultancy services. In addition, the company provides investment, marketing, private debt securities issuance, training, administrative, show agency, condotel, golf resort, cable car and related support, creative and art, project and construction management, offshore financing, karaoke, payment and collection agency, loyalty programme, garbage collection and disposal, sewerage, investment trading, reinsurance, and resort management services. Further, it offers electricity supply, water, liquefied petroleum gas, and other services at Genting Highlands; operates sportsbooks; owns and operates aircraft; owns sea vessels; researches and develops software; and operates a video lottery facility. The company was formerly known as Resorts World Bhd. Genting Malaysia Berhad was incorporated in 1980 and is headquartered in Kuala Lumpur, Malaysia

Full GMALY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this GMALY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GMALY vs SCHDGMALY vs JEPIGMALY vs OGMALY vs KOGMALY vs MAINGMALY vs ABBVGMALY vs MRKGMALY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.